Abstract
Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity. It is currently estimated that nearly 15% of the general population has some degree of renal damage, a figure that reaches 50% in at-risk subgroups. Renin-angiotensin-aldosterone system (RAAS) inhibitors represent the agents of choice to control hypertension and reduce urinary albumin excretion, thereby delaying renal function deterioration. Greater blockade of the RAAS either by the combined use of multiple drugs or by supramaximal doses of single agents may provide greater renal protection. Furthermore, it has been proposed especially in the presence of proteinuria. However, at this time there is insufficient evidence to routinely recommend this therapeutic approach in patients with chronic kidney disease. The present article examines the currently available evidence and practical implications of pharmacological disruption of RAAS activity for renal protection.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive treatment, chronic kidney disease, hypertension, progression, proteinuria, renin-angiotensin-aldosterone system, diabetes, urinary albumin
Current Pharmaceutical Design
Title: RAAS Inhibition and Renal Protection
Volume: 18 Issue: 7
Author(s): Leoncini Giovanna, Viazzi Francesca and Pontremoli Roberto
Affiliation:
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive treatment, chronic kidney disease, hypertension, progression, proteinuria, renin-angiotensin-aldosterone system, diabetes, urinary albumin
Abstract: Chronic kidney disease has become a major public health problem worldwide mainly as a consequence of the emerging epidemic of hypertension, diabetes, and obesity. It is currently estimated that nearly 15% of the general population has some degree of renal damage, a figure that reaches 50% in at-risk subgroups. Renin-angiotensin-aldosterone system (RAAS) inhibitors represent the agents of choice to control hypertension and reduce urinary albumin excretion, thereby delaying renal function deterioration. Greater blockade of the RAAS either by the combined use of multiple drugs or by supramaximal doses of single agents may provide greater renal protection. Furthermore, it has been proposed especially in the presence of proteinuria. However, at this time there is insufficient evidence to routinely recommend this therapeutic approach in patients with chronic kidney disease. The present article examines the currently available evidence and practical implications of pharmacological disruption of RAAS activity for renal protection.
Export Options
About this article
Cite this article as:
Giovanna Leoncini, Francesca Viazzi and Roberto Pontremoli, RAAS Inhibition and Renal Protection, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436520
DOI https://dx.doi.org/10.2174/138161212799436520 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Targeting Mitochondria for Cardiac Protection
Current Drug Targets Vitamin D and Cardio-Metabolic Risk Factors in Overweight Adults: An Overview of the Evidence
Current Pharmaceutical Design Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology An Update in the Management of Obesity: The Weight of CNS Targets
Recent Patents on CNS Drug Discovery (Discontinued) Assessment and Management of Volume Overload Among Patients on Chronic Dialysis
Current Vascular Pharmacology Beta-Blockers: Effects on Bone Mineral Density and Fracture Risk
Current Rheumatology Reviews Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Pregnancy and Sleep Apnea
Current Respiratory Medicine Reviews Pharma Emerging Market’s Scaning by Look and Feel of its Opportunities and Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs JAK2 as a Molecular Marker in Myeloproliferative Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews The Potential Clinical Properties of Magnesium
Current Medicinal Chemistry Bioactive Peptides - Are There More Antihypertensive Mechanisms Beyond ACE Inhibition?
Current Pharmaceutical Design The Role of Intracellular 35-Cyclic Adenosine Monophosphate (cAMP) in Atherosclerosis
Current Vascular Pharmacology The Role of the Thrombospondins in Healing Myocardial Infarcts
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effect of Resveratrol dose and Duration of Treatment on Blood Pressure in Patients with Cardiovascular Disorders: A Systematic Review
Current Drug Discovery Technologies